BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cordis Corporation today announced the presentation of the INCRAFT™ AAA Stent-Graft System INNOVATION study one-year results at the 2012 Veith Symposium in New York ...

Aortic aneurysm disease is among the leading cause of death in the U.S., estimated to affect 1.7 million people over the age of 55. The incidence for abdominal aortic aneurysms (AAA), a bulging, ...

New Clinical Data from PANDORA and ENGAGE Affirm Market-Leading Medical Device's Durable, Consistent and Proven Outcomes In Endovascular Treatment of Abdominal Aortic Aneurysms MINNEAPOLIS --The ...

Latest Results from Two Clinical Studies Show Strong Mid-Term Performance of Leading Medical Device for Endovascular Repair of Abdominal Aortic Aneurysms MINNEAPOLIS -- For endovascular repair of ...

Please provide your email address to receive an email when new articles are posted on . In patients who received a stent graft for endovascular abdominal aortic aneurysm repair, rates of ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued an alert recommending operators not routinely use a stent graft system for treatment of patients ...

The US Food and Drug Administration (FDA) has long kept a watchful eye over successive iterations of endovascular stent graphs in the Endologix AFX line, designed for repair of abdominal aortic ...

Endologix’s current commercial EVAR products include the AFX®2 Endovascular AAA System and the ALTO® Abdominal Stent Graft System. On October 1, 2020, Endologix became a private company, wholly owned ...

Medtronic (Minneapolis) has received FDA approval to sell its Endurant AAA stent graft system in the U.S. for the minimally invasive treatment of AAA, a largely unknown and often fatal condition.

MinnPost’s journalists are out in the community to report on the things that are happening in Minnesota. Your support right now will help fund their work AND keep our news paywall-free. It’s taken two ...